Jeffrey W. Albers sold $449k of KYMR
director at Kymera Therapeutics, Inc.. 5,000 shares at an average of $89.76, traded Dec 8, 2025, filed Dec 8, 2025.
Score components
- +15RoleDirector
- +17Trade size$449k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-311505, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 8, 2025 | MOption exercise Common Stock10b5-1 | +5,000 | $14.18 | $71k | 5,000 | Dec 8, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stock10b5-1 | -2,748 | $89.32 | $245k | 2,252 | Dec 8, 2025 |
| Dec 8, 2025 | SOpen-market sale Common Stock10b5-1 | -2,252 | $90.30 | $203k | 0 | Dec 8, 2025 |
| Dec 8, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 7,000 | Dec 8, 2025 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 20Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $7.4M 81,866 shares | -2% | |
| 23Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $2.3M 30,000 shares | -4% | |
| 40Moderate | Kymera Therapeutics, Inc. | Pamela Esposito director | $2.3M 27,563 shares | -100% | |
| 55Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $22M 236,588 shares | -6% | |
| 50Moderate | KYMRbuy Kymera Therapeutics, Inc. | Baker Bros. Advisors LP director, owner | $172M 2,005,813 shares | +376% | |
| 30Weak | Kymera Therapeutics, Inc. | Jared Gollob Chief Medical Officer | $4.4M 49,307 shares | -31% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $8.9M 100,000 shares | -13% | |
| 23Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $1.8M 30,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.